Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Athira Pharma, Inc. (ATHA)
|
Add to portfolio |
|
|
|
| Price: |
$13.07
| | Metrics |
| OS: |
38.1
|
M
| |
-53
|
% ROE
|
| Market cap: |
$497
|
M
| |
-140
|
% ROIC
|
|
Net cash:
|
$196
|
M
| |
$5.16
|
per share
|
|
EV:
|
$301
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($110)
|
M
| |
|
|
| EPS |
($2.58)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 61.5 | 0.0 | 42.8 | 0.0 | 13.3 | 0.0 | 0.0 |
| Revenue growth | 43.6% | | 222.1% | | | | |
| Cost of goods sold | 61.5 | 64.0 | 64.0 | 20.0 | 20.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | -64.0 | -21.2 | -20.0 | -6.7 | 0.0 | 0.0 |
| Gross margin | 0.0% | | -49.6% | | -50.5% | | |
| Selling, general and administrative | | 0.0 | | 0.0 | | | |
| Research and development | | | | | | 3.8 | 3.6 |
| General and administrative | 32.6 | 0.0 | 21.2 | 0.0 | 6.7 | 1.7 | 1.4 |
| EBIT | -94.0 | -55.9 | -64.0 | -18.3 | -18.7 | -5.4 | -5.0 |
| EBIT margin | -153.0% | | -149.6% | | -140.6% | | |
| Pre-tax income | -95.6 | -54.9 | -54.9 | -20.0 | -20.0 | -5.2 | -5.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -95.6 | -54.9 | -54.9 | -20.0 | -20.0 | -5.2 | -5.1 |
| Net margin | -155.6% | | -128.2% | | -150.2% | | |
| |
| Diluted EPS | ($2.53) | ($1.49) | ($1.49) | ($1.67) | ($1.67) | ($1.45) | ($1.47) |
| Shares outstanding (diluted) | 37.7 | 36.9 | 36.9 | 12.0 | 12.0 | 3.6 | 3.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|